AstraZeneca cut approximately 600 commercial sales jobs from its United States respiratory and immunology teams on November 13, 2026. The reductions are part of a three-year restructuring initiative incurring up to $2 billion in one-time costs to generate $1.5 billion in annual pretax savings. Chief Executive Officer Pascal Soriot plans to redeploy these resources into oncology and rare disease drug development as the company targets $80 billion in revenue by 2030 despite recent trial setbacks.
Details of United States sales job cuts
- ▪At least some of the AstraZeneca staff affected by the cuts of about 600 jobs were responsible for marketing asthma drugs Breztri and Airsupra
- ▪AstraZeneca scaled back its contract with Syneos Health, a partner company used to sell drugs in the United States
- ▪AstraZeneca cut approximately 600 commercial sales jobs from its United States respiratory and immunology teams on November 13, 2026
Three-year restructuring and reinvestment plan
- ▪AstraZeneca announced in October 2026 that its three-year cost-savings program would incur one-time restructuring costs of up to $2 billion
- ▪AstraZeneca's United States sales job reductions are part of a three-year cost-savings program aimed at achieving $1.5 billion in annual pretax savings
- ▪Chief Executive Officer Pascal Soriot said AstraZeneca plans to reinvest annual pretax savings from sales restructuring mainly into developing new drugs
CEO Pascal Soriot on strategic priorities and challenges
- ▪AstraZeneca Chief Executive Officer Pascal Soriot cited loss of patent protection for heart drug Farxiga and blood thinner Brilinta as reasons to redeploy resources
- ▪AstraZeneca Chief Executive Officer Pascal Soriot faces investor pressure over clinical trial setbacks while pursuing an $80 billion annual revenue target by 2030
Financial context of respiratory and immunology division
- ▪Top sellers in AstraZeneca's respiratory division include asthma inhaler Symbicort and severe asthma antibody drug Fasenra
- ▪AstraZeneca's respiratory and immunology division generated $2.5 billion, representing 16 percent of total revenue, during the third quarter of 2026
- ▪AstraZeneca asthma inhaler Airsupra has faced United States pricing pressure since launching in 2024, while Breztri saw rapid adoption for COPD
AstraZeneca United States operations
- ▪AstraZeneca pledged to invest $50 billion in the United States to expand manufacturing operations and generate tens of thousands of jobs
- ▪AstraZeneca maintains a workforce of more than 25,000 employees across its operations in the United States
GSK strategy and relocation
- ▪GSK Plc plans to relocate its research and development headquarters to Cambridge, United Kingdom, near AstraZeneca's global headquarters
- ▪Rival drugmaker GSK Plc is reducing costs to fund pipeline development before patent protection expires on an HIV drug before 2030
Story comments
Loading comments…